Scientific journal: Reduce CNS drug development timelines by up to 40%
CNS drug development is complex, and partnering with an integrated CRO/CDMO can reduce your timelines by up to 40%. Learn more in The Altascientist.
List view / Grid view
CNS drug development is complex, and partnering with an integrated CRO/CDMO can reduce your timelines by up to 40%. Learn more in The Altascientist.
VIVACOAT® A shows outstanding adhesion to tablet cores achieved by using globally accepted excipients. Low adhesion can be the reason for the frequently observed effect of "logo bridging“.
Lipid-based Nano Particles form a very useful class of delivery systems in the pharmaceutical area as well as in cosmetics (and food/nutraceuticals).
In a continuous process, mono-functional excipients must be added through individual feeders, possibly resulting in multiple sources of variability.
SGS PACE is a seamless combination of world-leading development, bioanalysis and clinical research through one point of contact.
A paper has shown how machine learning (ML) models predicted the inkjet printing printability of drug formulations with high accuracy.
Massachusetts Institute of Technology researchers have developed an algorithm that extracts powder particle size distribution from laser speckle in real-time.
SGS’s biosafety centre of excellence in Glasgow has received the Business Leadership Award at Scotland's Life Sciences Annual Awards 2023.
A paper has reviewed how novel drug delivery systems could achieve stable formulations of nucleic acid therapeutics.
5 April 2023 | By Oxford Instruments
This webinar showcases the use of cryogen-free benchtop nuclear magnetic resonance (NMR) spectroscopy and relaxometry – from R&D to process development and manufacturing scale up.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the first dual-combination, inhaled corticosteroid and long-acting beta2-agonist reliever therapy for mild asthma.
This ebook explores the potential of nanoparticle formulations for drug delivery, as well techniques to predict in vivo bioavailability of these dosage forms.
Innovative technologies were identified as potential solutions for enhancing bioavailability in ocular drug delivery in a research review.
COVID-19 and multiple sclerosis patients experienced reduced inflammation when given the first nasal monoclonal antibody in a pilot trial.
Designed to treat anxiety and postpartum depression, a biotherapeutics company has made natural allopregnanolone orally bioavailable without permanent chemical modification.